The acute respiratory distress syndrome: pathophysiology, current clinical practice, and emerging therapies
- PMID: 30431366
- DOI: 10.1080/17476348.2018.1548280
The acute respiratory distress syndrome: pathophysiology, current clinical practice, and emerging therapies
Abstract
More than fifty years after the first description of acute respiratory distress syndrome (ARDS) by Ashbaugh and colleagues, no specific treatment of the underlying pathophysiological processes is available. The current therapeutic regime is comprised of supportive measures such as lung protective ventilation, restrictive fluid management, paralyzing drugs, and prone positioning. Although vast improvements have been made in ARDS-treatment during the last five decades, mortality among patients with severe ARDS remains at an unacceptable rate of 45%. Areas covered: This article reviews the evolution of the currently used definition, established pathophysiological mechanism, highlights the current best clinical practice to treat ARDS, gives a brief outlook on cutting edge trends in ARDS research and closes with an expert opinion on the subject. Expert commentary: Individualizing the provided measures to specific genotypes is the key challenge in ARDS research today. The ongoing digital revolution will help to individualize ARDS-treatment and will therefore presumably improve survival and quality of life.
Keywords: Acute respiratory distress syndrome; cell therapy; lung protective ventilation; nitric oxide; prone positioning.
Similar articles
-
Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment.JAMA. 2018 Feb 20;319(7):698-710. doi: 10.1001/jama.2017.21907. JAMA. 2018. PMID: 29466596 Review.
-
[Therapy of acute respiratory distress syndrome : Survey of German ARDS centers and scientific evidence].Anaesthesist. 2015 Apr;64(4):277-85. doi: 10.1007/s00101-015-0010-1. Epub 2015 Apr 1. Anaesthesist. 2015. PMID: 25824000 German.
-
Acute Respiratory Distress Syndrome Novel Therapies.Crit Care Nurs Q. 2019 Oct/Dec;42(4):411-416. doi: 10.1097/CNQ.0000000000000281. Crit Care Nurs Q. 2019. PMID: 31449151
-
Acute respiratory distress syndrome.Dis Mon. 1996 May;42(5):270-326. doi: 10.1016/s0011-5029(96)90016-4. Dis Mon. 1996. PMID: 8625776 Review.
-
Prone positioning in acute respiratory distress syndrome.Nurs Stand. 2015 Aug 12;29(50):34-9. doi: 10.7748/ns.29.50.34.e9261. Nurs Stand. 2015. PMID: 26264335 Review.
Cited by
-
Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways.Biomol Biomed. 2023 May 1;23(3):457-470. doi: 10.17305/bb.2022.8549. Biomol Biomed. 2023. PMID: 36724020 Free PMC article.
-
Natural product derived phytochemicals in managing acute lung injury by multiple mechanisms.Pharmacol Res. 2021 Jan;163:105224. doi: 10.1016/j.phrs.2020.105224. Epub 2020 Sep 29. Pharmacol Res. 2021. PMID: 33007416 Free PMC article. Review.
-
Knockdown of circ_0001679 alleviates lipopolysaccharide-induced MLE-12 lung cell injury by regulating the miR-338-3p/ mitogen-activated protein kinase 1 axis.Bioengineered. 2022 Mar;13(3):5803-5817. doi: 10.1080/21655979.2022.2034564. Bioengineered. 2022. PMID: 35264058 Free PMC article.
-
Human umbilical cord mesenchymal stromal cell small extracellular vesicle transfer of microRNA-223-3p to lung epithelial cells attenuates inflammation in acute lung injury in mice.J Nanobiotechnology. 2023 Aug 25;21(1):295. doi: 10.1186/s12951-023-02038-3. J Nanobiotechnology. 2023. PMID: 37626408 Free PMC article.
-
Allosteric regulation of Keap1 by 8β-hydroxy-α-cyclocostunolide for the treatment of acute lung injury.Acta Pharm Sin B. 2024 Sep;14(9):4174-4178. doi: 10.1016/j.apsb.2024.06.025. Epub 2024 Jun 28. Acta Pharm Sin B. 2024. PMID: 39309504 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources